AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11878727
Drug: GA, paracetamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural bupivacaine (Bupi)
Trial: 11878727
Drug: GA, paracetamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural saline (Saline)
Trial: 11878727
Drug: GA, paracetamol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA, paracetamol, NSAID (GA)
Trial: 3138609
Drug: Low-dose animal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose animal antigen injection
Trial: 28973650
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% bupivacaine with 150 μg clonidine (clonidine group, n = 116)
Trial: 28973650
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% bupivacaine alone (control group, n = 109)
Trial: 26519614
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction plus treatment as usual
Trial: 24480956
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of ramosetron
Trial: 24480956
Drug: 0.075 mg
RxNorm normalized name: mestranol 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg of palonosetron
Trial: 21149771
Drug: 2-hour daily
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour daily patching of the sound eye
Trial: 21149771
Drug: 5 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 sessions of acupuncture weekly
Trial: 8540115
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) + transrectal ultrasonography (TRUS)
Trial: 24695721
Drug: Baclofen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (60 mg/d; 20 mg t.i.d.)
Trial: 17992118
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1+)
Trial: 17992118
Drug: Combined anti-inflammatory/angiostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above plus rofecoxib 25 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+)
Trial: 17992118
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy (arm A)
Trial: 17992118
Drug: Combined anti-inflammatory/angiostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anti-inflammatory/angiostatic treatment (arm B)
Trial: 15224207
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of rosiglitazone (4 mg b.i.d.) to gliclazide (160 mg/day)
Trial: 15224207
Drug: Uptitration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitration of gliclazide to a maximum of 320 mg/day
Trial: 11786526
Drug: LY333531 (protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY333531 (protein kinase Cbeta inhibitor)
Trial: 390528
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of atenolol daily
Trial: 390528
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of atenolol daily
Trial: 390528
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of atenolol daily (control)
Trial: 6121762
Drug: Atenolol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (various doses)
Trial: 390528
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 mg daily)
Trial: 30201237
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus ketamine (0.1 mg/kg morphine plus 0.2 mg/kg ketamine)
Trial: 30201237
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus placebo (0.1 mg/kg morphine plus normal saline)
Trial: 23872799
Drug: IV pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV pamidronate (1 mg/kg)
Trial: 21769048
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg twice daily)
Trial: 19254614
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all 3 devices
Trial: 12062893
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg paroxetine
Trial: 2492744
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (74 mumol.kg‐1.d‐1) during 11 postoperative days
Trial: 982547
Drug: Suramin (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suramin (4-6 g)
Trial: 11561266
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of mepivacaine (Group I)
Trial: 11561266
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of mepivacaine (Group II)
Trial: 11561266
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL twice with an interval of 5 minutes (Group III)
Trial: 11561266
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL twice with an interval of 10 minutes (Group IV)
Trial: 30667591
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release tacrolimus tablets (LCPT) 0.07-0.13 mg/kg/day
Trial: 30667591
Drug: Twice-daily immediate-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily immediate-release tacrolimus capsules (IR-Tac) 0.10-0.15 mg/kg/day
Trial: 30667591
Drug: Once-daily extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily extended-release tacrolimus tablets (LCPT)
Trial: 30667591
Drug: Twice-daily immediate-release
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily immediate-release tacrolimus capsules (IR-Tac)
Trial: 30413507
Drug: Digital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital treatment programme (Joint Academy) for 3 months
Trial: 30413507
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (BOA) for 3 months
Trial: 25191967
Drug: Methacholine (MCh)
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methacholine (MCh) challenge with deep inspirations (DIs) taken immediately after the last dose
Trial: 25191967
Drug: Methacholine (MCh)
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methacholine (MCh) challenge with DIs taken 30 minutes after the last dose
Trial: 22718089
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 vaccine (200 μg dose)
Trial: 22718089
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 vaccine (60 μg dose)
Trial: 22718089
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 vaccine (20 μg dose)
Trial: 22718089
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 vaccine
Trial: 22718089
Drug: hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hepatitis A vaccine/placebo control
Trial: 16149143
Drug: High-dose interferon-α2b
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interferon-α2b (10 MU daily for 3 weeks, then 5 MU/TIW) plus ribavirin (1,000-1,200 mg/d) for 21 weeks, continued until week 48 if negative HCV RNA PCR.
Trial: 7703820
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment for partners of drinkers
Trial: 7703820
Drug: Group treatment
RxNorm normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group treatment for partners of drinkers
Trial: 7703820
Drug: No-treatment waiting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment waiting list control
Trial: 786665
Drug: Acetylcysteine 600
RxNorm normalized name: acetylcysteine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine 600 mg daily, 3 days a week for 6 months
Trial: 31995214
Drug: Behavioral health‐virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral health‐virtual patient navigation program (video contact in ED and telephonic outreach 24 to 72 hours after discharge, then weekly for up to 45 days)
Trial: 22594305
Drug: Rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole sodium (20 mg daily) for 4 weeks
Trial: 19383241
Drug: Sinus rhythm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinus rhythm control with aspirin (group 1)
Trial: 19383241
Drug: Sinus rhythm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinus rhythm control with warfarin (group 2)
Trial: 17447980
Drug: 5% calcipotriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% calcipotriol cream
Trial: 15953083
Drug: Moisturizing cream
RxNorm normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing cream
Trial: 8203766
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (320 mg per day for four weeks)
Trial: 28903476
Drug: AdVEGF‐DΔNΔC gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdVEGF‐DΔNΔC gene therapy
Trial: 12589843
Drug: ME inflation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME inflation and antibiotics (oral Amoxicillin 500 mg 3/day) for 10 days
Trial: 9113191
Drug: Ketamine 50
RxNorm normalized name: ketamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 50 mg x 4 per day dissolved in juice
Trial: 8272492
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream 5% applied for 15 to 30 minutes
Trial: 3476505
Drug: 150 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms/ml sanguinaria and 0.2% zinc chloride (Rinse B)
Trial: 3476505
Drug: 300 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms/ml sanguinaria and no zinc chloride (Rinse C)
Trial: 3476505
Drug: 300 micrograms/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms/ml sanguinaria and 0.2% zinc chloride (Rinse D)
Trial: 3476505
Drug: Placebo oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral rinse (Rinse A)
Trial: 21968596
Drug: 3T (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3T (triple target treatment)
Trial: 18477086
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg/ml
Trial: 18477086
Drug: Levobupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 7.5 mg/ml
Trial: 9851651
Drug: Gabapentin 500
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg/day for 6 months (Group A)
Trial: 9851651
Drug: Gabapentin 1000
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1000 mg/day for 6 months (Group B)
Trial: 9851651
Drug: Gabapentin 500
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 500 mg/day for 6 months followed by 1000 mg/day for 6 months (Group C)
Trial: 9851651
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group D) receiving only symptomatic treatment
Trial: 2529986
Drug: Selenium supplement
RxNorm normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplement (150 micrograms/d for 21 days)
Trial: 6104295
Drug: Trimazosin (TMZ)
RxNorm normalized name: TMZ
DrugBank: Trimazosin (DB09206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimazosin (TMZ) treatment for up to 52 weeks
Trial: 26786567
Drug: 0.5% C.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% C. indicum water extract cosmetic cream
Trial: 26786567
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no extract) cosmetic cream
Trial: 25180636
Drug: Collagen implant
RxNorm normalized name: Collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen implant with gentamicin sulphate (Collatamp(®))
Trial: 22577263
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus monotherapy
Trial: 17633971
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zoledronic acid annually
Trial: 11786572
Drug: G-CSF (lenograstim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (lenograstim) 5 microg/kg/d from day 7 until ANC > or = 500/microL sustained over 48 hours after two induction courses.
Trial: 11786572
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G-CSF).
Trial: 26138423
Drug: Invasive‐noninvasive sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive‐noninvasive sequential mechanical ventilation (MV)
Trial: 15896827
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg/day for 8 weeks
Trial: 14998786
Drug: Arginine boluses
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine boluses (1-60 mg/kg) injected intravenously at 29-min intervals for 120 min
Trial: 7977853
Drug: Hyperinsulinemic hypoglycemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic hypoglycemia (H; 2.5 mmol/l)
Trial: 7977853
Drug: Hyperinsulinemic euglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic euglycemia (E; 4.5 mmol/l)
Trial: 2531510
Drug: ISDN (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN (standard release formulation) 40 mg administered 6 times daily (240 mg total)
Trial: 2531510
Drug: ISDN (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN (40 mg) administered 4 times daily
Trial: 2531510
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of glycerol trinitrate (3 mg/h)
Trial: 2531510
Drug: Oral ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ISDN (standard release formulation) administered 4-6 times daily
Trial: 2531510
Drug: Nitrate therapy
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate therapy providing constant doses over time (e.g. I.V. nitroglycerin)
Trial: 26186450
Drug: S. frutescens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. frutescens 1,200 mg twice daily
Trial: 9286131
Drug: Short-term psychiatric
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychiatric inpatient treatment in another hospital.
Trial: 8329826
Drug: Low-dose GHRH(1-29)-NH2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GHRH(1-29)-NH2 (LD group; n = 15) at 30 micrograms/kg/day s.c. in three daily doses
Trial: 8329826
Drug: High-dose GHRH(1-29)-NH2
RxNorm normalized name: GHRH(1-44)NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GHRH(1-29)-NH2 (HD group; n = 12) at 60 micrograms/kg/day s.c. in three daily doses
Trial: 8329826
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH group; n = 16) at 0.1 IU/kg/day s.c. once daily
Trial: 3329851
Drug: FD group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FD group (154 micrograms fentanyl plus 5.5 mg droperidol i.v.)
Trial: 3329851
Drug: FV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FV group (127 micrograms fentanyl plus 6.7 mg Valium)
Trial: 27644633
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg ginger powder, twice a day for 3 days)
Trial: 21609911
Drug: Betahistine dihydrochloride
RxNorm normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine dihydrochloride treatment after Epley's maneuver (EM)
Trial: 21609911
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with betahistine after EM)
Trial: 18313995
Drug: Oseltamivir phosphate
RxNorm normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate preparation 1
Trial: 18313995
Drug: Oseltamivir phosphate
RxNorm normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate preparation 2
Trial: 10319352
Drug: Treatment (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (three different methods)
Trial: 10319352
Drug: Control (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (16 patients observed without treatment)
Trial: 9172005
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation A (furosemide, 500 mg)
Trial: 9172005
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation B (furosemide, 500 mg)
Trial: 6398127
Drug: Methylprednisolone (MPN)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MPN) 375 mg
Trial: 6398127
Drug: Low-dose metoclopramide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoclopramide (MCP) 60 mg
Trial: 28988340
Drug: Core decompression
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Core decompression plus saline injection
Trial: 26338095
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every two weeks (120 Q2W)
Trial: 26338095
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every four weeks (120 Q4W)
Trial: 26338095
Drug: Tabalumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab (both dosing regimens)
Trial: 16925195
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous ketorolac (Toradol), 0.25% subcutaneous bupivacaine (Marcaine) with epinephrine along the incision, and 0.25% bupivacaine in the rectus fascia
Trial: 1387778
Drug: Inocoterone 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inocoterone 10% solution
Trial: 30357272
Drug: Recombinant alkaline
RxNorm normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alkaline phosphatase 1.6 mg/kg
Trial: 30357272
Drug: Recombinant alkaline
RxNorm normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alkaline phosphatase 0.4 mg/kg
Trial: 30357272
Drug: Recombinant alkaline
RxNorm normalized name: Human recombinant alkaline phosphatase
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant alkaline phosphatase 0.8 mg/kg
Trial: 23390781
Drug: Combination 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination 5-fluoruracil (5-FU) with cisplatinum